VERAXA Biotech (NASDAQ: VRXA) announced on July 9, 2026, that it has begun cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing.
ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate. VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to streamline the path to clinical trials for its most advanced oncology candidate. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties. These statements are based on information available as of the date hereof, and the company undertakes no duty to update this information unless required by law. For full terms of use and disclaimers, please see http://IBN.fm/Disclaimer.
